3-Beta-Hydroxy-Delta-5-c27-Steroid Dehydrogenase Deficiency

3-beta-hydroxy-delta-5-c27-steroid dehydrogenase deficiency is a very rare inherited liver disease. It is one of the bile acid synthesis disorders. In this condition, the liver cannot make normal primary bile acids properly because the HSD3B7 enzyme does not work well. When this enzyme is missing or weak, unusual bile acids build up, normal bile flow becomes poor, and the body cannot absorb fat and fat-soluble vitamins well. This can lead to jaundice, liver injury, poor growth, bleeding, rickets, and even cirrhosis if the disease is not recognized early.

3-beta-hydroxy-delta-5-c27-steroid dehydrogenase deficiency is also called HSD3B7 deficiency, congenital bile acid synthesis defect type 1, CBAS1, or 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency. It is a rare inherited liver disease. The body cannot make normal primary bile acids well, so bile flow becomes weak, fat absorption becomes poor, and vitamins A, D, E, and K may become low. Babies often develop cholestasis, jaundice, pale stool, poor growth, and fatty stool, but some people present later in childhood or even adulthood. The most important treatment is bile acid replacement, especially cholic acid.

This disease happens because the HSD3B7 gene does not work properly. That gene helps the liver make normal bile acids from cholesterol. When the enzyme is missing or weak, the liver produces abnormal bile acid intermediates instead of healthy bile acids. These abnormal chemicals can injure the liver, while the lack of normal bile acids reduces bile flow and reduces absorption of fats and fat-soluble vitamins. That is why patients can have jaundice, poor weight gain, bleeding from vitamin K deficiency, weak bones from vitamin D deficiency, vision problems from vitamin A deficiency, and nerve or muscle problems from vitamin E deficiency.

The best-studied disease-specific treatment is oral primary bile acid replacement. FDA labeling states that CHOLBAM (cholic acid) is indicated for bile acid synthesis disorders due to single enzyme defects, and HSD3B7 deficiency falls in that group. Reviews and long-term studies report that oral cholic acid can improve liver tests, improve growth, reduce toxic bile acid production, and help many children avoid liver transplantation when started early. Some reports also describe benefit from chenodeoxycholic acid / chenodiol in this disorder, but the FDA-approved indication of current chenodiol labeling is for CTX, not for HSD3B7 deficiency, so that use is specialist and case-based.

This disorder is also important because it is treatable. Many babies and children improve when the disease is found early and treated with primary bile acid replacement. Doctors often think about it in infants or children who have cholestasis with normal or low gamma-glutamyl transferase (GGT), poor absorption of fats, and deficiency of vitamins A, D, E, and K.

Another names

This disease has several other names. The most used names are HSD3B7 deficiency, 3β-HSD deficiency, 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency, and congenital bile acid synthesis defect type 1 (CBAS1). All of these names describe the same disorder. The short form CBAS1 is often used in genetics and liver disease reports.

Types

There are no many separate classic clinical “types” like in some other diseases. It is mainly one genetic disorder, but doctors may describe it in practical forms according to how it appears in real life. These include: neonatal or infantile cholestatic form, late childhood liver disease form, fat-soluble vitamin deficiency form, bleeding-predominant form, rickets or bone disease form, cirrhosis or liver failure form, and mild or atypical form with delayed diagnosis. These are not different genes; they are different ways the same disease can show itself.

Causes

This disease does not usually have 20 separate unrelated causes like an infection or common fever. The true cause is biallelic disease-causing variants in the HSD3B7 gene, meaning a child receives a harmful gene change from each parent. To match your requested format honestly, the 20 points below explain the main cause and the different genetic ways that cause can happen.

1. The main cause is a harmful change in the HSD3B7 gene, which gives instructions for making the 3β-HSD7 enzyme in liver cells.

2. A missense variant can change one amino acid in the enzyme and make it weak or unstable.

3. A nonsense variant can create an early stop signal, so the enzyme is cut short and cannot work normally.

4. A frameshift variant can disturb the gene reading frame and produce an abnormal enzyme.

5. A splice-site variant can make the cell process the gene message incorrectly, which may remove important parts of the enzyme.

6. A small deletion in the gene can remove needed DNA and block normal enzyme production.

7. A small insertion can also disrupt the gene and damage enzyme structure.

8. A child may have homozygous variants, meaning the same harmful variant is inherited from both parents.

9. A child may have compound heterozygous variants, meaning two different harmful HSD3B7 variants are inherited, one from each parent.

10. The inheritance pattern is autosomal recessive, so the disease appears when both gene copies are affected.

11. Carrier parents are a common underlying family reason. Each parent usually has one altered copy but is healthy.

12. When both parents are carriers, each pregnancy has a risk of an affected child.

13. A family history of unexplained neonatal cholestasis can point to the same inherited gene defect in relatives.

14. Consanguinity can increase the chance that a child receives the same rare altered gene from both sides of the family.

15. Some variants reduce enzyme activity only partly, causing a milder or delayed form.

16. Some variants nearly remove enzyme function, causing early and severe infant disease.

17. The enzyme defect blocks an early step in making cholic acid and chenodeoxycholic acid, the main primary bile acids.

18. Because normal bile acids are low, bile flow falls, and cholestasis develops.

19. At the same time, atypical hepatotoxic bile acids build up and can directly injure the liver.

20. The final disease picture comes from both poor bile acid production and toxic bile acid accumulation, which together cause liver disease and vitamin deficiency.

Symptoms

1. Jaundice is very common. The skin and eyes become yellow because bile pigments build up when bile flow is poor. In babies, this may continue beyond the normal newborn period and should not be ignored.

2. Cholestasis means bile does not move out of the liver properly. This is the central problem in the disease and leads to many of the other symptoms.

3. Hepatomegaly means an enlarged liver. Doctors often find this on examination because the liver becomes swollen from injury and trapped bile products.

4. Splenomegaly can happen in some patients, especially when liver disease becomes more advanced and portal pressure rises.

5. Poor weight gain or failure to thrive may appear because the child cannot absorb fats and calories well.

6. Diarrhea or greasy stools can happen because normal bile acids are needed to digest and absorb fats. When bile acids are low, fat stays in the stool.

7. Vitamin K deficiency bleeding may cause easy bruising, nosebleeds, bleeding from procedures, or abnormal blood clotting tests.

8. Vitamin D deficiency rickets can cause soft bones, delayed growth, bone pain, or bowed legs in children.

9. Vitamin E deficiency may lead to nerve problems over time because fat-soluble vitamins are poorly absorbed in cholestatic disease.

10. Vitamin A deficiency can affect vision, especially in dim light, and can also affect skin and immune health.

11. Dark urine may appear because conjugated bilirubin enters the urine when cholestasis is present.

12. Pale stools can happen because less bile pigment reaches the intestine. This can be a warning sign of cholestatic liver disease.

13. Itching is often absent or mild in this disorder, which can help doctors separate it from some other cholestatic conditions.

14. Cirrhosis and liver failure symptoms may develop later if the disease is missed. These can include abdominal swelling, weakness, enlarged spleen, and worsening jaundice.

15. Some patients show recurrent liver disease or delayed diagnosis in childhood, with repeated illness, poor growth, coagulopathy, or chronic liver damage rather than obvious early neonatal signs.

Diagnostic tests

The diagnosis usually needs a mix of physical examination, laboratory study, special bile acid testing, imaging, and genetic testing. One very important clue is cholestasis with normal or low GGT and sometimes unexpectedly low or normal total serum bile acids on routine testing, because standard tests may miss the unusual bile acids in this condition.

Physical exam tests:

1. General inspection for jaundice helps the doctor see yellow skin and sclera, which can be an early clue to cholestatic disease.

2. Growth measurement checks weight, length, and head growth. Poor growth suggests chronic malabsorption or chronic liver disease.

3. Abdominal palpation for liver enlargement helps detect hepatomegaly. A large liver is common in affected infants and children.

4. Abdominal palpation for splenic enlargement helps detect splenomegaly, which may suggest more advanced liver disease or portal hypertension.

Manual tests:

5. Clinical assessment of stool color is simple but useful. Pale stools support cholestasis and poor bile delivery to the gut.

6. Diet and feeding review helps identify fat intolerance, greasy stool, poor feeding, and failure to thrive. These are indirect but important bedside clues.

7. Bleeding history review looks for bruising, nosebleeds, gum bleeding, or bleeding after minor procedures, suggesting vitamin K deficiency.

8. Bone and limb examination can show signs of rickets such as bone tenderness, widened wrists, or leg deformity when vitamin D deficiency is severe.

Lab and pathological tests:

9. Direct and total bilirubin help confirm cholestasis. Direct bilirubin is usually raised in cholestatic liver disease.

10. Liver enzymes such as AST and ALT help show liver cell injury, though they do not by themselves make the diagnosis.

11. Gamma-glutamyl transferase (GGT) is especially useful because it is often normal or low in HSD3B7 deficiency despite cholestasis.

12. Routine serum total bile acids may be low or normal, which can be misleading because common tests may not measure the abnormal bile acids well.

13. Coagulation profile such as PT/INR checks for vitamin K deficiency and liver synthetic dysfunction.

14. Fat-soluble vitamin levels for vitamins A, D, E, and K help measure malabsorption and complications of cholestasis.

15. Urine bile acid analysis by mass spectrometry is one of the key tests. It detects the unusual 3β-hydroxy-Δ5 bile acids that strongly suggest the diagnosis.

16. Plasma or serum bile acid profiling by LC-MS/MS can also show abnormal bile acid patterns and help confirm a bile acid synthesis defect.

17. Molecular genetic testing of HSD3B7 confirms the diagnosis by finding disease-causing variants in both gene copies.

18. Liver biopsy may be used when diagnosis is unclear. It can show giant cell hepatitis, cholestasis, inflammation, fibrosis, or cirrhosis, but it is not specific by itself.

Electrodiagnostic test:

19. Nerve conduction study or electromyography is not a routine first-line test for this disease, but it may be used in selected patients with neurological problems caused by long-standing vitamin E deficiency or related complications.

Imaging tests:

20. Abdominal ultrasound is commonly used to look at liver size, spleen size, texture, and to help rule out other causes of cholestasis such as blockage or structural disease. In advanced cases, other imaging like CT may show cirrhotic changes and splenomegaly.

Non-pharmacological treatments

1) Specialist liver follow-up. Regular care with a pediatric or adult hepatology team is one of the most important non-drug treatments. The purpose is early detection of worsening cholestasis, poor growth, vitamin deficiency, portal hypertension, or liver failure. The mechanism is simple: frequent review allows treatment changes before damage becomes severe.

2) Early genetic confirmation. Genetic testing does not treat the disease directly, but it prevents delay. The purpose is to confirm HSD3B7 deficiency fast so bile acid replacement can begin early. The mechanism is earlier diagnosis, earlier correct treatment, and fewer wrong treatments.

3) Urine bile acid testing. Specialized urine bile acid analysis is a key non-drug management tool. The purpose is diagnosis and treatment monitoring. The mechanism is that abnormal bile acid patterns fall when therapy is working.

4) Growth monitoring. Children with this disorder may fail to thrive. The purpose is to catch malnutrition early. The mechanism is repeated weight, length, and head-growth checks that guide calorie support and vitamin replacement.

5) High-calorie nutrition planning. Many children need more calories than usual. The purpose is to support growth and healing when fat absorption is poor. The mechanism is giving enough energy in forms the child can absorb better.

6) Careful fat planning. Dietitians often adjust fat quality and quantity rather than removing all fat. The purpose is to reduce steatorrhea while still supporting growth. The mechanism is matching dietary fat intake to bile flow and tolerance.

7) Essential fatty acid support. Chronic cholestatic liver disease can lead to essential fatty acid deficiency. The purpose is to protect growth, skin, and brain development. The mechanism is supplying needed fats in monitored amounts.

8) Fat-soluble vitamin monitoring. Vitamins A, D, E, and K often need repeated blood checks. The purpose is to find low levels before symptoms become serious. The mechanism is laboratory surveillance followed by dose adjustment.

9) Bone health care. Bone weakness can happen when vitamin D and nutrition are poor. The purpose is to prevent rickets or osteopenia. The mechanism is monitoring growth, vitamin D status, calcium intake, and physical activity.

10) Itch control without medicine first. Gentle skin care, short nails, cool rooms, soft cotton clothes, and regular moisturizers can reduce damage from scratching. The purpose is comfort and skin protection. The mechanism is reducing skin irritation and heat-related itch triggers.

11) Bleeding-risk observation. Easy bruising or nosebleeds can signal vitamin K deficiency. The purpose is to prevent serious bleeding. The mechanism is quick recognition of warning signs and fast treatment.

12) Sunlight and safe activity. Safe outdoor activity supports general health and can help bone health when nutrition is corrected. The purpose is stronger bones and better development. The mechanism is movement, muscle use, and support of vitamin D status.

13) Infection prevention. Good handwashing, vaccine review with the clinician, and quick care for fever matter more in advanced liver disease. The purpose is to reduce extra stress on the liver. The mechanism is lowering infection burden.

14) Stool and urine monitoring at home. Parents can watch for pale stool, dark urine, oily stool, or worsening jaundice. The purpose is early detection of relapse or poor control. The mechanism is simple home observation between visits.

15) Abdominal monitoring. A bigger belly can mean hepatomegaly, splenomegaly, or ascites. The purpose is early detection of progression. The mechanism is routine physical exams and ultrasound when needed.

16) Psychosocial support for family. Rare disease care is stressful. The purpose is to improve treatment adherence, clinic attendance, and nutrition routines. The mechanism is education, counseling, and practical support.

17) Multidisciplinary care. Hepatology, genetics, nutrition, transplant medicine, and primary care should work together. The purpose is better whole-person care. The mechanism is coordinated decisions rather than fragmented care.

18) Serial liver testing. Repeated ALT, AST, bilirubin, INR, albumin, and GGT checks are essential. The purpose is to measure control and detect worsening liver function. The mechanism is objective lab tracking over time.

19) Imaging surveillance. Ultrasound helps check liver size, spleen size, cirrhosis signs, and ascites. The purpose is structural monitoring. The mechanism is noninvasive imaging to find complications early.

20) Early transplant referral when needed. This is not first-line care, but referral should happen before full collapse if liver failure develops. The purpose is to save life in severe disease. The mechanism is timely assessment before the child becomes too sick.

Drug treatments

1) Cholic acid. This is the most important FDA-approved drug for single-enzyme bile acid synthesis disorders. Class: primary bile acid. Typical FDA dosage: 10 to 15 mg/kg/day orally once daily or in two divided doses. Purpose: replace missing bile acid and suppress toxic abnormal bile acid formation. Mechanism: cholic acid acts through bile acid pathways including FXR-related regulation of bile acid homeostasis. Common adverse effects in trials included diarrhea; liver function must be monitored because worsening liver tests can require stopping treatment.

2) Chenodeoxycholic acid / chenodiol. This is another primary bile acid with published benefit in HSD3B7 deficiency, although current FDA labeling for CTEXLI is for CTX in adults, not HSD3B7 deficiency. Class: bile acid. FDA CTEXLI dose for CTX: 250 mg orally three times daily. Purpose in specialist off-label use: suppress abnormal bile acid synthesis and improve cholestasis. Mechanism: product replacement and feedback suppression of toxic intermediates. Important risk: hepatotoxicity, so liver tests must be checked.

3) Ursodiol. Ursodiol is not the preferred disease-specific replacement for HSD3B7 deficiency, but some clinicians may use it in selected cholestatic situations. Class: hydrophilic bile acid. Purpose: improve bile flow and reduce cholestatic symptoms in some settings. Mechanism: action in the liver, bile, and gut lumen alters bile composition. It is not a true replacement for the missing primary bile acids in HSD3B7 deficiency, so it should not replace specialist-directed primary bile acid therapy.

4) Vitamin K1 (phytonadione). Class: fat-soluble vitamin used as a drug for deficiency and hypoprothrombinemia. Purpose: reduce bleeding risk when vitamin K absorption is poor in cholestasis. Mechanism: restores vitamin-K-dependent clotting factor production. Oral absorption may be poor if bile salts are low, which is important in cholestatic disease. The exact dose depends on age, route, and severity, so it must be prescribed individually.

5) Vitamin E. Class: fat-soluble antioxidant vitamin. Purpose: protect nerves, muscles, and cells when malabsorption causes deficiency. Mechanism: reduces oxidative injury in cell membranes. In cholestasis, vitamin E deficiency can persist unless bile acid replacement and tailored supplementation are both used. Dose must be individualized by age and blood level.

6) Vitamin A. Class: fat-soluble vitamin. Purpose: support vision, immune function, and epithelial health in deficiency states. Mechanism: retinoid-dependent effects on eye and tissue function. It may be needed in cholestatic children, but too much vitamin A can also be harmful, so blood monitoring matters.

7) Vitamin D. Class: fat-soluble vitamin/hormone precursor. Purpose: reduce the risk of weak bones and poor mineralization. Mechanism: improves calcium and phosphate handling. Because cholestatic liver disease often reduces absorption, many patients need monitored supplementation rather than casual over-the-counter use.

8) Calcium. Class: mineral supplement used like a treatment when intake or absorption is low. Purpose: support bones and growth, especially when vitamin D is low. Mechanism: provides substrate for bone mineralization. It is usually paired with vitamin D and nutrition care.

9) Medium-chain triglyceride oil. This is nutrition support rather than a classic drug, but it is often used like a medical treatment. Purpose: give calories that are absorbed more easily than long-chain fats. Mechanism: MCT absorption depends less on normal micelle formation than many other fats.

10) Multivitamin preparations designed for cholestasis. Purpose: give combined support for several common deficiencies. Mechanism: easier routine replacement and improved adherence. Exact product and dose vary by age and lab results.

11) Rifampin for severe itch. In cholestatic liver disease, specialists sometimes use rifampin for pruritus. Purpose: reduce disabling itch. Mechanism: modulation of itch pathways and bile-related mediators. This is symptom control only, not disease correction.

12) Cholestyramine for itch. Purpose: bind bile-related substances in the gut in selected patients with cholestatic pruritus. Mechanism: intestinal binding may reduce itch triggers. It is supportive only and can interfere with absorption of other treatments, so timing matters.

13) Spironolactone. Purpose: treat fluid buildup such as ascites in advanced liver disease. Mechanism: potassium-sparing diuresis lowers sodium and water retention. It is for complications, not for the enzyme defect itself.

14) Furosemide. Purpose: sometimes added when ascites or edema is not controlled well enough. Mechanism: loop diuresis increases salt and water excretion. Careful monitoring is needed to avoid dehydration and kidney problems.

15) Lactulose. Purpose: treat or prevent hepatic encephalopathy in advanced liver failure. Mechanism: lowers ammonia production and absorption in the gut. This is not common in early treated HSD3B7 deficiency, but may be needed in decompensated cirrhosis.

16) Rifaximin. Purpose: added for recurrent hepatic encephalopathy in advanced liver disease. Mechanism: reduces ammonia-producing gut bacteria. This is complication management only.

17) Albumin infusion. This is a medical therapy rather than a home drug. Purpose: support circulation in selected patients with severe ascites or after large-volume drainage. Mechanism: expands plasma volume and helps prevent circulatory dysfunction.

18) Antibiotics for cholangitis or spontaneous bacterial peritonitis when present. Purpose: treat infection quickly because infection can worsen liver failure. Mechanism: bacterial control reduces systemic inflammation and organ stress. Drug choice depends on culture, age, and severity.

19) Blood products when severe bleeding occurs. Vitamin deficiency and liver failure can increase bleeding risk. Purpose: emergency stabilization. Mechanism: replacement of missing blood components while the cause is corrected.

20) Post-transplant immunosuppressive medicines. These do not treat the genetic defect directly, but they become essential after liver transplant. Purpose: prevent rejection of the new liver. Mechanism: controlled immune suppression so the transplanted liver survives. Exact drugs and doses depend on the transplant team.

Dietary molecular supplements

The most useful supplements in this disease are usually the fat-soluble vitamins and nutrition supports used to correct malabsorption. These are not casual wellness supplements. They should be guided by a clinician because both deficiency and overdose are possible in liver disease.

1) Vitamin A. 2) Vitamin D. 3) Vitamin E. 4) Vitamin K. 5) Calcium. 6) Zinc. 7) Essential fatty acid blends. 8) MCT oil. 9) High-calorie protein formulas. 10) Cholestasis-focused multivitamin formulas. The purpose of these supplements is to correct malabsorption, support growth, protect nerves and bones, reduce bleeding risk, and improve overall nutrition. The mechanism differs by nutrient, but the shared principle is that cholestasis reduces normal absorption, so patients often need more careful replacement than healthy people. Exact dosing must be individualized by age, weight, blood levels, stool losses, and liver status.

Immunity booster / regenerative / stem cell drugs

There is no FDA-approved stem-cell drug, regenerative drug, or true “immunity booster” that corrects HSD3B7 deficiency itself. The evidence-based disease treatment is bile acid replacement, not stem-cell therapy. So the safest and most truthful answer is that these therapies are not standard of care for this disease today.

In severe end-stage cases, the closest real-world “regenerative” pathway is liver transplantation, after which immune-modifying drugs such as tacrolimus, mycophenolate, corticosteroids, basiliximab, antithymocyte globulin, or similar transplant medicines may be used by specialists to protect the new liver. These drugs are not immunity boosters, and they are not cures for the genetic mutation. They are transplant-support medicines used only in selected patients.

Surgeries or procedures

Surgery is not the main treatment for this disease. Most patients should first receive bile acid replacement and nutrition care. Procedures are considered mainly when complications appear or when liver failure is advanced.

1) Liver transplantation is done when cirrhosis or liver failure becomes severe and other treatment is not enough. It replaces the failing liver and can be life-saving. 2) Liver biopsy may be done when diagnosis is unclear or tissue information is needed. 3) Endoscopy with variceal treatment may be needed if portal hypertension leads to bleeding varices. 4) Paracentesis may be done when ascites is large or needs diagnosis. 5) Feeding tube placement may be considered in severe malnutrition when oral intake is not enough.

Prevention points

Because this is a genetic disease, you usually cannot prevent the mutation itself after birth. What you can do is prevent complications. Important steps are: early diagnosis, early bile acid therapy, regular liver tests, regular vitamin checks, good nutrition follow-up, growth monitoring, fast review of jaundice or pale stool, bleeding-risk awareness, quick care for fever or abdominal swelling, and early transplant referral when liver disease progresses.

When to see a doctor

See a doctor urgently if there is jaundice, pale stool, dark urine, easy bruising, nosebleeds, poor feeding, vomiting, swelling of the belly, severe itching, poor growth, confusion, sleepiness, blood in stool or vomit, or fever in a child with liver disease. These can signal worsening cholestasis, vitamin deficiency, ascites, bleeding, infection, or liver failure.

Foods to eat and what to avoid

Good food choices should be tailored by a liver dietitian, but general helpful ideas are: eat calorie-rich foods if growth is poor, medically supervised protein, foods with safe calcium, doctor-guided vitamin support, and easy-to-digest meals split through the day. Avoid or limit unplanned high-fat heavy meals if they worsen steatorrhea, alcohol, unsafe herbal products, megadoses of vitamins without testing, and crash diets. In advanced liver disease with ascites, salt restriction may also be advised by the care team.

Frequently asked questions

1) Is this disease curable? The gene defect is not currently cured, but the liver disease can often be controlled very well with early bile acid replacement.

2) What is the best treatment? Cholic acid is the most evidence-based and FDA-approved disease-specific treatment for single-enzyme bile acid synthesis disorders.

3) Is ursodiol enough? Usually not as the main disease-specific therapy for HSD3B7 deficiency. Primary bile acid replacement is more directly targeted.

4) Can adults have it? Yes. Although many cases start in infancy, some people present later.

5) Why are vitamins low? Because poor bile acid production reduces fat and fat-soluble vitamin absorption.

6) Which vitamins matter most? A, D, E, and K are the key ones to monitor.

7) Can it cause cirrhosis? Yes, if diagnosis and treatment are delayed.

8) Can children grow normally? Many can do very well when treated early and followed closely.

9) Is transplant always needed? No. Early effective bile acid treatment can help many patients avoid transplant.

10) Is there a stem-cell cure? Not an established evidence-based one for this disease today.

11) Is it inherited? Yes, it is an inherited disorder linked to HSD3B7 variants.

12) What tests are used for follow-up? Liver tests, vitamin levels, growth checks, urine bile acid studies, and imaging are commonly used.

13) Can bleeding happen? Yes, especially if vitamin K is low.

14) Can itching happen? Yes, cholestatic liver disease can cause pruritus.

15) What improves outcome most? Early recognition and early bile acid replacement.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: March 10, 2025.